IL128736A0 - Methods using cre-lox for production of recombinant adeno-associated viruses - Google Patents
Methods using cre-lox for production of recombinant adeno-associated virusesInfo
- Publication number
- IL128736A0 IL128736A0 IL12873697A IL12873697A IL128736A0 IL 128736 A0 IL128736 A0 IL 128736A0 IL 12873697 A IL12873697 A IL 12873697A IL 12873697 A IL12873697 A IL 12873697A IL 128736 A0 IL128736 A0 IL 128736A0
- Authority
- IL
- Israel
- Prior art keywords
- lox
- cre
- production
- methods
- associated viruses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2532396P | 1996-09-06 | 1996-09-06 | |
PCT/US1997/015691 WO1998010086A1 (fr) | 1996-09-06 | 1997-09-04 | Procede d'utilisation de cre-lox pour la production de virus adeno-associes de recombinaison |
Publications (1)
Publication Number | Publication Date |
---|---|
IL128736A0 true IL128736A0 (en) | 2000-01-31 |
Family
ID=21825356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12873697A IL128736A0 (en) | 1996-09-06 | 1997-09-04 | Methods using cre-lox for production of recombinant adeno-associated viruses |
Country Status (7)
Country | Link |
---|---|
US (2) | US6274354B1 (fr) |
EP (1) | EP0950111A1 (fr) |
JP (1) | JP2001500014A (fr) |
AU (1) | AU722375B2 (fr) |
CA (1) | CA2264499A1 (fr) |
IL (1) | IL128736A0 (fr) |
WO (1) | WO1998010086A1 (fr) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6924128B2 (en) * | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
US6720140B1 (en) | 1995-06-07 | 2004-04-13 | Invitrogen Corporation | Recombinational cloning using engineered recombination sites |
US6143557A (en) * | 1995-06-07 | 2000-11-07 | Life Technologies, Inc. | Recombination cloning using engineered recombination sites |
AU724922B2 (en) | 1995-06-07 | 2000-10-05 | Invitrogen Corporation | Recombinational cloning using engineered recombination sites |
JP2001506132A (ja) * | 1996-12-18 | 2001-05-15 | ターゲティッド ジェネティクス コーポレイション | Aavベクターの産生における使用のためのリコンビナーゼ活性化可能aavパッケージングカセット |
US5851808A (en) | 1997-02-28 | 1998-12-22 | Baylor College Of Medicine | Rapid subcloning using site-specific recombination |
US6995006B2 (en) * | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
CA2303768C (fr) | 1997-09-19 | 2009-11-24 | The Trustees Of The University Of Pennsylvania | Procedes et produits genetiques vectoriels utiles pour obtenir un virus adeno-associe (aav) |
US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
CA2307016A1 (fr) | 1997-10-24 | 1999-05-06 | Life Technologies, Inc. | Clonage recombinatoire au moyen d'acides nucleiques possedant des sites de recombinaison |
US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
GB9810423D0 (en) * | 1998-05-15 | 1998-07-15 | Cancer Res Campaign Tech | Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
AU774643B2 (en) | 1999-03-02 | 2004-07-01 | Invitrogen Corporation | Compositions and methods for use in recombinational cloning of nucleic acids |
JP4693244B2 (ja) * | 1999-03-18 | 2011-06-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法 |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US8715940B2 (en) | 1999-04-06 | 2014-05-06 | Wisconsin Alumni Research Foundation | Method of making recombinant influenza virus |
US6893865B1 (en) * | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
US7115391B1 (en) * | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
US6995010B1 (en) | 1999-10-29 | 2006-02-07 | Takara Bio Inc. | Gene transfer method |
US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
US6838285B2 (en) * | 2001-09-18 | 2005-01-04 | Becton Dickinson | Site specific recombinase based method for producing adenoviral vectors |
WO2003040318A2 (fr) * | 2001-11-02 | 2003-05-15 | Intradigm Corporation | Procede et systeme de clonage recombinatoire inductible de cellules bacteriennes |
NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
DE10159167A1 (de) * | 2001-12-03 | 2003-10-02 | Guenter Cichon | Expressionssystem |
PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
JP4769417B2 (ja) | 2001-12-17 | 2011-09-07 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | アデノ随伴ウイルス(aav)血清型9の配列、それを含むベクターおよびその使用 |
AU2003237805A1 (en) * | 2002-04-09 | 2003-10-27 | Cornell Research Foundation, Inc. | Use of aav integration efficiency element for mediating site-specific integration of a transcription unit |
WO2004028243A2 (fr) | 2002-08-21 | 2004-04-08 | Revivicor, Inc. | Porcins ne presentant aucune expression de l'alpha 1,3-galactosyltransferase fonctionnelle |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
ATE469984T1 (de) | 2003-12-01 | 2010-06-15 | Life Technologies Corp | Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon |
WO2005062812A2 (fr) * | 2003-12-22 | 2005-07-14 | The Johns Hopkins University | Systeme a base de raav pour la disruption genique de cellules somatiques |
GB0415963D0 (en) * | 2004-07-16 | 2004-08-18 | Cxr Biosciences Ltd | Detection of cellular stress |
CA2574953A1 (fr) | 2004-07-26 | 2006-02-09 | Dow Global Technolgies Inc. | Procede permettant d'ameliorer l'expression d'une proteine par mise au point d'une souche par genie genetique |
AU2006292827B2 (en) | 2005-08-09 | 2013-02-14 | Revivicor, Inc. | Transgenic ungulates expressing CTLA4-IG and uses thereof |
JP2010504909A (ja) * | 2006-09-14 | 2010-02-18 | メドジェニクス・メディカル・イスラエル・リミテッド | 長期持続性の医薬製剤 |
US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
CN101688213A (zh) | 2007-04-27 | 2010-03-31 | 陶氏环球技术公司 | 用于快速筛选微生物宿主以鉴定某些在表达异源蛋白质方面具有改善的产量和/或质量的菌株的方法 |
CN103260649A (zh) | 2010-06-15 | 2013-08-21 | 迈德詹尼克斯医疗以色列有限公司 | 长效药物制剂 |
WO2015038958A1 (fr) | 2013-09-13 | 2015-03-19 | California Institute Of Technology | Récupération sélective |
SI3116900T1 (sl) | 2014-03-09 | 2021-02-26 | The Trustees Of The University Of Pennsylvania | Sestavki uporabni pri zdravljenju pomanjkanja ornitin transkarbamilaze(OTC) |
WO2015191508A1 (fr) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Capsides chimériques |
MX2017005834A (es) | 2014-11-05 | 2017-11-17 | Voyager Therapeutics Inc | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. |
AU2015346162B2 (en) | 2014-11-14 | 2022-02-10 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
CN112375760A (zh) | 2014-11-14 | 2021-02-19 | 沃雅戈治疗公司 | 调节性多核苷酸 |
WO2016094783A1 (fr) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions et méthodes pour la production de scaav |
EP3719134B1 (fr) * | 2015-03-11 | 2023-08-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Vecteurs de rp2 pour le traitement de la rétinite pigmentaire liée au chromosome x |
EP3294309A4 (fr) * | 2015-05-14 | 2019-01-16 | St. Jude Children's Research Hospital, Inc. | Molécules d'acide nucléique contenant des espaceurs et leurs procédés d'utilisation |
AU2016338565B2 (en) | 2015-10-14 | 2021-11-18 | Audentes Therapeutics, Inc. | Nucleic acid molecules containing spacers and methods of use thereof |
WO2017100671A1 (fr) | 2015-12-11 | 2017-06-15 | California Institute Of Technology | Peptides de ciblage pour diriger des virus adéno-associés (aav) |
WO2017189959A1 (fr) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions pour le traitement de maladies |
EP3448987A4 (fr) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | Compositions pour le traitement de maladies |
SG11201809699XA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Modulatory polynucleotides |
RU2764587C2 (ru) | 2016-05-18 | 2022-01-18 | Вояджер Терапьютикс, Инк. | Способы и композиции для лечения хореи гентингтона |
US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症(als)治療組成物および方法 |
SG11201909868YA (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
CN111132626B (zh) | 2017-07-17 | 2024-01-30 | 沃雅戈治疗公司 | 轨迹阵列引导系统 |
SG11202000840YA (en) | 2017-07-31 | 2020-02-27 | Reflection Biotechnologies Ltd | Cellular models of and therapies for ocular diseases |
KR20200044793A (ko) | 2017-08-03 | 2020-04-29 | 보이저 테라퓨틱스, 인크. | Aav의 전달을 위한 조성물 및 방법 |
JP2021502060A (ja) | 2017-10-16 | 2021-01-28 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症(als)の治療 |
WO2019079242A1 (fr) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Traitement de la sclérose latérale amyotrophique (sla) |
GB201800903D0 (en) | 2018-01-19 | 2018-03-07 | Oxford Genetics Ltd | Vectors |
EP3807404A1 (fr) | 2018-06-13 | 2021-04-21 | Voyager Therapeutics, Inc. | Régions 5' non traduites (5'utr) modifiées pour la production d'aav |
US20210355454A1 (en) | 2018-07-24 | 2021-11-18 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
US11149256B2 (en) | 2018-09-26 | 2021-10-19 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
KR20210068068A (ko) | 2018-09-28 | 2021-06-08 | 보이저 테라퓨틱스, 인크. | 조작된 프로모터를 갖는 프라탁신 발현 구축물 및 그의 사용 방법 |
US20210348242A1 (en) | 2018-10-04 | 2021-11-11 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
TW202028458A (zh) | 2018-10-05 | 2020-08-01 | 美商航海家醫療公司 | 編碼腺相關病毒(aav)生產蛋白之經基因工程化核酸構築體 |
EP3867389A1 (fr) | 2018-10-15 | 2021-08-25 | Voyager Therapeutics, Inc. | Vecteurs d'expression pour la production à grande échelle de raav dans le système baculovirus/sf9 |
AU2020208467A1 (en) | 2019-01-18 | 2021-08-05 | Voyager Therapeutics, Inc. | Methods and systems for producing AAV particles |
KR20210130158A (ko) | 2019-01-31 | 2021-10-29 | 오레곤 헬스 앤드 사이언스 유니버시티 | Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법 |
GB201901571D0 (en) * | 2019-02-05 | 2019-03-27 | Oxford Genetics Ltd | Inducible AAV sysyem |
TW202106879A (zh) | 2019-04-29 | 2021-02-16 | 美商航海家醫療公司 | 於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法 |
EP4010465A1 (fr) | 2019-08-09 | 2022-06-15 | Voyager Therapeutics, Inc. | Milieu de culture cellulaire destiné à être utilisé dans la production de produits de thérapie génique dans des bioréacteurs |
US20220364114A1 (en) | 2019-08-26 | 2022-11-17 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
US20220307055A1 (en) * | 2019-08-28 | 2022-09-29 | University Of Florida Research Foundation, Incorporated | Improved production of recombinant aav using embryonated avian eggs |
WO2022015788A1 (fr) * | 2020-07-14 | 2022-01-20 | Abeona Therapeutics Inc. | Vecteurs viraux adéno-associés recombinés pour la délivrance de gènes multiples |
US20230227802A1 (en) | 2020-07-27 | 2023-07-20 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
WO2022026410A2 (fr) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc | Compositions et méthodes pour le traitement de la maladie de niemann-pick de type c1 |
AU2021319208A1 (en) * | 2020-07-30 | 2023-03-02 | Shape Therapeutics Inc. | Stable cell lines for inducible production of rAAV virions |
EP4192514A1 (fr) | 2020-08-06 | 2023-06-14 | Voyager Therapeutics, Inc. | Milieu de culture cellulaire destiné à être utilisé dans la production de produits de thérapie génique dans des bioréacteurs |
KR20230085170A (ko) | 2020-10-15 | 2023-06-13 | 에프. 호프만-라 로슈 아게 | 동시 유전자 활성화를 위한 핵산 구조체 |
US20240141378A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2022187473A2 (fr) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Expression contrôlée de protéines virales |
WO2023091949A2 (fr) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions et méthodes de traitement de troubles neurologiques liés à un déficit en bêta glucosylcéramidase |
WO2023240236A1 (fr) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale |
WO2024054983A1 (fr) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Expression controlée de protéines virales |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) * | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
EP0728214B1 (fr) * | 1993-11-09 | 2004-07-28 | Medical College Of Ohio | Lignees cellulaires stables aptes a exprimer le gene de replication du virus adeno-associe |
DE69433592T2 (de) * | 1993-11-09 | 2005-02-10 | Targeted Genetics Corp., Seattle | Die erzielung hoher titer des rekombinanten aav-vektors |
WO1996017947A1 (fr) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Lignees cellulaires d'encapsidation utilisees pour la generation de titres hauts de vecteurs aav recombinants |
CA2228269C (fr) * | 1995-08-03 | 2008-01-08 | Avigen, Inc. | Systeme d'auxiliaires d'efficacite elevee pour la production de vecteurs d'aav |
-
1997
- 1997-09-04 EP EP97939821A patent/EP0950111A1/fr not_active Withdrawn
- 1997-09-04 US US09/242,743 patent/US6274354B1/en not_active Expired - Lifetime
- 1997-09-04 IL IL12873697A patent/IL128736A0/xx unknown
- 1997-09-04 WO PCT/US1997/015691 patent/WO1998010086A1/fr not_active Application Discontinuation
- 1997-09-04 JP JP10512948A patent/JP2001500014A/ja active Pending
- 1997-09-04 CA CA002264499A patent/CA2264499A1/fr not_active Abandoned
- 1997-09-04 AU AU41830/97A patent/AU722375B2/en not_active Ceased
-
2001
- 2001-08-07 US US09/923,726 patent/US6428988B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1998010086A1 (fr) | 1998-03-12 |
JP2001500014A (ja) | 2001-01-09 |
EP0950111A1 (fr) | 1999-10-20 |
US20020102714A1 (en) | 2002-08-01 |
US6274354B1 (en) | 2001-08-14 |
AU4183097A (en) | 1998-03-26 |
AU722375B2 (en) | 2000-08-03 |
US6428988B1 (en) | 2002-08-06 |
CA2264499A1 (fr) | 1998-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL128736A0 (en) | Methods using cre-lox for production of recombinant adeno-associated viruses | |
AU9397098A (en) | Methods and cell line useful for production of recombinant adeno-associated viruses | |
HUP0001762A3 (en) | Method for producing recombinant virus | |
HUP0001271A3 (en) | Method for purifying recombinant adenovirus | |
AU7565694A (en) | Methods and compositions for the large scale production of recombinant adeno-associated virus | |
AU2639095A (en) | Recombinant hk2 polypeptide | |
AU1628895A (en) | Recombinant virus | |
AU3119895A (en) | Recombinant virus vectors | |
AU3309997A (en) | Recombinant adeno-associated viral vectors | |
IL129759A0 (en) | Process for the preparation of benzyl-ethers | |
EP0761683A4 (fr) | Proteine ou polypeptide, procede et intermediaires permettant leur preparation | |
AU5689699A (en) | Methods of producing high titer recombinant adeno-associated virus | |
HUP9902710A3 (en) | Recombinant swinepox virus | |
HUT58371A (en) | Recombinant virus of marek-disease | |
HUP0001837A3 (en) | Novel dnas and process for producing proteins by using the same | |
EP0705901A3 (fr) | Procédé de séparation du profacteur IX recombinant du facteur IX recombinant | |
ZA9710271B (en) | Bicistronic recombinant viruses useful for the treatment of dyslipoproteinemia-related pathologies | |
AU7548291A (en) | Process for purifying polypeptide | |
HUP9903751A3 (en) | Intermediates for the preparation of 2-imidazoline-5-ones | |
GB9413316D0 (en) | Novel proteins | |
GR3035436T3 (en) | Process for the preparation of 2-H-heptafluoropropane | |
HU9403070D0 (en) | Improved method for recombinant protein production | |
ZA975823B (en) | Process for the production of recombinant adenoviruses. | |
IL116759A0 (en) | Process for the preparation of para-fluorophenol | |
GB9614823D0 (en) | Recombinant kynurenine-3-hydroxylase enzyme and process for its preparation |